Latest revenue
$14.4M
as of 2026-03-31
Latest net income
$-7.7M
as of 2026-03-31
Net margin
-53.4%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $384.2M
- Enterprise value
- $384.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $2.73
- 52-wk low
- $1.22
- Beta
- —
- Shares out
- 145.0M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Table of Contents Item 1. Business Overview OmniAb, Inc. licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological IntelligenceTM, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals…
AI summary unavailable — showing raw filing excerpt
Generated from OABI's filing dated 2026-03-04
Key risks
Table of Contents Item 1A. Risk Factors You should carefully consider the risks and uncertainties described below, together with the other information in this Annual Report, including our financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before making an investment in our securities. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and growth prospects. If that were to happen, the trading price of our securities could decline. Additional risks and…
AI summary unavailable — showing raw filing excerpt
Generated from OABI's filing dated 2026-03-04
Profitability
Operating margin
-369.5%
30.9%Net margin
-347.0%
47.6%Return on equity
-24.3%
12.5%Return on assets
-21.5%
13.0%Leverage
Debt / equity
0.13×
3.8%Debt / assets
11.3%
3.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $14.4M | +247.3% | $-7.7M | +57.7% | -53.4% |
Q4 2025 2025-12-31 | $8.4M | -22.5% | $-14.2M | -8.5% | -169.3% |
Q3 2025 2025-09-30 | $2.2M | -46.3% | $-16.5M | -0.9% | -738.1% |
Q2 2025 2025-06-30 | $3.9M | -48.8% | $-15.9M | -16.5% | -407.4% |
Q1 2025 2025-03-31 | $4.2M | +9.3% | $-18.2M | +4.0% | -438.1% |
Q4 2024 2024-12-31 | $10.8M | — | $-13.1M | — | -121.0% |
Q3 2024 2024-09-30 | $4.2M | -23.8% | $-16.4M | -4.0% | -392.4% |
Q2 2024 2024-06-30 | $7.6M | +9.6% | $-13.6M | +7.4% | -179.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Commercial Physical & Biological Research · SIC 8731
Your notes
Keep private notes on OABI — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$107.7K
Insider selling
$283.0K
Net activity
−$175.3K
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns OABI
Institutional value
$34.9M
Total shares held
22.5M
Distinct holders
74
-54 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8.1M | $12.7M | +41.9K (+0.5%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 4.0M | $6.3M | — | New |
| 3 | PRIVATE MANAGEMENT GROUP INC | 2.4M | $3.8M | +8.7K (+0.4%) | Added |
| 4 | DIMENSIONAL FUND ADVISORS LP | 1.7M | $2.7M | -407.3K (-18.9%) | Trimmed |
| 5 | TOWERVIEW LLC | 1.0M | $1.6M | +0 (+0.0%) | No change |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 903.8K | $1.4M | — | New |
| 7 | ISTHMUS PARTNERS, LLC | 756.7K | $1.2M | +35.4K (+4.9%) | Added |
| 8 | VANGUARD FIDUCIARY TRUST CO | 725.6K | $1.1M | — | New |
| 9 | Nuveen, LLC | 623.9K | $979.5K | -250.6K (-28.7%) | Trimmed |
| 10 | Bank of New York Mellon Corp | 274.5K | $430.9K | +5.8K (+2.2%) | Added |
| 11 | Arbiter Partners Capital Management LLC | 192.6K | $302.4K | +0 (+0.0%) | No change |
| 12 | RHUMBLINE ADVISERS | 159.2K | $250.0K | -3.5K (-2.2%) | Trimmed |
| 13 | Cornerstone Capital, Inc. | 142.3K | $223.4K | +33.1K (+30.3%) | Added |
| 14 | Invesco Ltd. | 135.1K | $212.1K | -1.2K (-0.9%) | Trimmed |
| 15 | JPMORGAN CHASE & CO | 120.1K | $187.4K | -173.1K (-59.0%) | Trimmed |
| 16 | UBS Group AG | 102.5K | $160.9K | +34.5K (+50.8%) | Added |
| 17 | DEUTSCHE BANK AG\ | 92.7K | $145.5K | +15.4K (+20.0%) | Added |
| 18 | SEI INVESTMENTS CO | 60.6K | $95.1K | +17.7K (+41.3%) | Added |
| 19 | Vanguard Global Advisers, LLC | 51.4K | $80.7K | — | New |
| 20 | WELLS FARGO & COMPANY/MN | 50.1K | $78.7K | -75.5K (-60.1%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once OABI's latest filing finishes processing.